Skip to main content
. 2024 Nov 21;30(43):4609–4619. doi: 10.3748/wjg.v30.i43.4609

Figure 2.

Figure 2

Quantitative analysis of SEPTIN9, SHOX2, RNF180 and EPO methylation in plasma specimens of controls (n = 102) and patients with different stages of esophageal cancer (n = 210). A-D: Quantitative analysis of SEPTIN9 (A), SHOX2 (B), RNF180 (C), and EPO (D) methylation in esophageal cancer patients with different stages and controls. The positive rates of SHOX2, RNF180, SEPTIN9, and EPO DNA methylation in EC patients with advanced stages were higher than those of EC patients with early stages and controls. aP < 0.05.